Synthesis, characterization and hypoglycemic activity of chromium(III) complexes with Gliclazide (GLC), Glibenclamide (GLB) and Glimeperide (GLM) oral antidiabetic allopathic drugs have been studied. The conductometric titration using monovariation method indicates that complexes are non-ionic and L 2 M type. Analytical data agrees with the molecular formulae of complexes viz., (C 15 Structure of complexes was assigned as octahedral in which ligand molecules lie horizontally joining the central chromium atom and two water molecules attached vertically with the metal. Infra-red spectral studies confirm the coordination of sulphonyl oxygen on one side and enolic oxygen from other side with metal ion, IR, Mass and 1 H-NMR studies supports structure IV for the complex proposed on the basis of analytical data. Magnetic susceptibility a suggest that the complexes are diamagnetic,
INTRODUCTION
Chromium is an essential metal that appears to have beneficial role in regulation of insulin action, metabolic syndrome and cardiovascular disease. Chromium function in our bodies is critical without it, the harmone insulin would not work. Most of the people are familiar with insulin as the shot diabetes give themselves in order to control their high blood sugar. But what most of the people don't realize is that insulin is the "Master hormone of our metabolism, it is not only controls blood sugar levels and many other aspects of carbohydrate break down and storage but also directs much of the metabolism involving fat, proteins and energy (calories). Because insulin requires chromium to function properly 1 . Chromium reduces insulin resistance, this essential trace element could therefore have wide ranging effects on high blood pressure and abnormal blood lipid in addition to lowering blood sugar Kaats et al., 3 suggest that supplementation with chromium picolinate can lead significant improvement in body consumption when a BCI (Body Consumption Index) is used as the outcome criterion that represent a sume of the net gain in non fat mass added to sum of the net looses of body fat. Chromium is a true potentiator of insulin and is known as glucose tolerance factor (GTF) trivalent chromium Cr(III) has been claimed to be a constituent of glucose tolerance factor. Schwartz and Mertz (1959) showed that trivalent chromium (Cr 3+ ) cured the impaired glucose tolerance observed in rats an a chromium deficient diet.
Pandey et al., 4 studied the Cr(III) complexes with Di-benzyl sulphide ligand.
Louise et al., 5 synthesized homoleptic trimethyl silylacetylide complex of Cr(III), LiF et al 6 ., Synthesize Cr(III) complex and compare antihyperglycemic activity shows enhanced antidiabetic activity.
Yang X et al 7 ., synthesize a new chromium complex-chromium (phenylalanine) improves insulin responsiveness and reduces whole body glucose tolerance.
Complexation of sulphonylueas with transition and inner transition metal has been studied in detail by Yoshinaga and Yamamotto [8] [9] (1966 a,b), Iqbal et al., 10 (1984, 1985, 1986 (1984) . In view of the above and in continuation of our work, it is interesting to have an insight into the synthesis of chromium(III) complexes with Gliclazide, Glibenclamide and Glimeperide and to study various structural aspects of the isolated complexes. here, the synthesis and characterization of chromium(III) complexes with sulphonyl ureas have been described.for following drugs. 26 ., (2000) .
EXPERIMENTAL

Ligand-Metal ratio
Synthesis of complexes
The chemicals used in this synthesis were all of analytical grade. A weighed quantity of Gliclazide, Glibenclamide and Glimeperide (2mol.) was dissolved separately in minimum quantity of 90% ethanol. The chromium chloride solution was prepared by dissolving it separately in the same solvent. Metallic solution was added slowely with stirring into the solution of the ligand at room temperature maintaining the pH between 6.0 to 6.5 by adding dilute NaOH solution. On refluxing the mixture for 3h and on cooling, the complexes separated out, which were filtered off, washed well with ethanol and finally dried in vacuum and weighed.
The elemental analysis of the isolated complexes were carried out using the reported method Jeffery et al 27 
RESULTS AND DISCUSSION
Infra-red spectral studies
The IR spectra of ligand and isolated complexes were recorded the range 4000-400 cm 
H-NMR Studies
The 1 H-NMR spectral data are given in (table 6 ). It was observed that the singlet due to the amide (NH) proton around (d8.74) in the spectrum of the ligand disappeared in the complex shows the formation of M-O band. This also confirms the deprotonation of amide NH group through enolisation (the appearance of > C=N stretching band observed in IR spectra) ( 
Hypoglycemic Studies
Pharmacology is mainly concerned with the responses of living organisms to chemical stimuli. One may further divide the subject from a medical view point, into pharmacodynamics and pharmacotherapy , the former is concerned with the response of living organism to chemical stimuli in the absence of disease, while the later with the response the organism to such stimuli in a pathogenic state. This is the phase of pharmacology (i.e. pharmacotherapy) which is of special interest to the physician.
Pharmacotherapy includes the treatment of the sick with drugs and therefore is of prime importance in practice of medicine. It is fundamental to the health-economy of the people. A compound or a complex which is to be recommended as a drug of utility, must be capable of easy absorption and excretion. It is also essential that neither the absence itself nor the metabolic products thereof should exercise toxicity or any adverse side effect to the patient [55] [56] [57] 
Preparation of Enteric Coated Grannules
Make a blend of drug and lactose paste the blend through 100# sieve HPMC-5CPS is dissolved in water (2% solution) keep the starch/ 
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Hypoglycemic Study on animals(Folin Wu method) 68 Pharmacological studies were carried out on male albino rats weighing 150 to 200 g. Animals were divided in three groups A, B and C each group containing eleven animals, so selected that the total weight of animals in each group remained the same. Animals of all the three groups were kept in experimental conditions and were fed on a fixed particular diet (i.e. milk and bread). When animals were acclimatized to the laboratory conditions then fasting blood sugar was estimated colorimetrically (as abridged in Table 5 ) for four days using Folin and Wu method 17 to ascertain an average blood sugar level. On fourth day doses of Gliclazide, Glibenclamide and Glimeperide were given separately to the animals of group A, B and C respectively In case of group (A) animals, after the oral administration of Gliclazide (5.0 mg/kg) fall in blood sugar was noted with increasing duration of time i.e. after ½, 1½, 3½ and 5½ hours. 
2.0 ml. supernatant liquid of the sample + 2 ml. 2 ml. glucose solution 2 ml. glucose + 2 ml. Harding's B-solution 2 ml. Cu reagent + 2 ml.
Harding's B-solution (NaHCO II glucose/100 ml. of blood in mg.
The peak time of the effect of Gliclazide has been found to be 1 to 2 hours and duration of action to be 4 to 6 hours.
Thereafter animals of group A, were further maintained for normal blood glucose level by way of feeding them on same experimental diet for three more days (i.e. without giving drug or complex). On the 8 th day when it was confirmed that all the eleven animals of this groups have returned to their normal blood sugar level, then only the animals were orally administered a dose of Gliclazide-Cr(III) complex (5.0 mg/kg) and fasting blood glucose was recorded again with increasing duration of time (table 8) Taking fresh groups of animals and using the same procedure, hypoglycemic activity of Glibenclamide and Glimeperide (oral antidiabetics) were also studied and compared with their complexes. In case of Glibenclamide fasting blood sugar was recorded after 2, 4, 6, 8 and 10 hrs. The peak time of the effect of these drugs was proved to be about 4 to 6 hrs. and duration of action to be upto 10 to 12 hrs. After the administration of drugs On the days of administration of drugs or its complex the diet was given to the animals after final observation i.e. at 2.0 p.m. to group A animals and 4.0 p.m. to the animals of group B and C (Table 6-8).
As the reported metal complexes of Gliclazide, Glibenclamide and Glimeperide drugs are able to dissociate at stomach pH, therefore its dosages, to be given to subject animals should be such that it should not be dissociate in stomach i.e. at pH 1.2 for this complexes prepared enteric coated to make at the drug bioavailable as it is, i.e. at duodenum and small intestinal pH (5.5 to 6.8 pH)
Drug is coated with a polymer HPMC-5CPS (Hydroxy propylmethyl cellulose) which does not permit drug to dissolve in stomach (i.e. pH 1.2) and such polymer dissolves rapidly at dedenal pH (5 above 5.5) thus drug releases at 5.5 pH and is available for absorption. At this pH complex at stable, non-dissociatable and absorbable. Therefore dosage forms for animals study is prepared as enteric coated, polymerized in this dosage forms are not soluble at pH 12. This drug delivery system is adopted for further study [60] [61] [62] [63] [64] [65] [66] [67] 
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On IV day drug was administered orally. On VII day complex was administered orally at 7.35 am. The hypoglycemic effects of Gliclazide, Glibenclamide and Glimeperide the well known sulphonyl ureas, were inverstigated on the blood sugar levels of male albino rats by using Folin Wu method. 68 . Analysis of data presented in This blood sugar lowering effect of sulphonyl ureas seems to be related to the stimulation of insulin secretion on the other hand, many studies have strongly indicated the presence of long term or extra pancreatic action of sulphonyl ureas 69 . The hypoglycemic activity of sulphonyl ureas may also be attributed to the stimulation of glycolysis and to the inhibition of glycogenesis in the liver by itself or by enhancing insulin action.
Further, on comparing the hypoglycemic effect of complexes of these sulphonyl ureas in relation to time, it becomes evident from tables 2, 3 and 4 that on the whole the maximum fall in blood sugar was observed after 1½. 6.0 and 5.0 hrs. with the administration of Gliclazide, Glibenclamide and Glimeperide complexes respectively. On comparing the hypoglycemic effect of these complxes with their parent drugs, it was revealed that in the three groups Gliclazide-Cr(III), Glibenclamide-Cr(III) and Glimeperide-Cr(III) treated albino rat had lowest blood sugar level being 49.72 mg/100 ml., 45.45 mg/100 ml. and 53.46 mg/100 ml. respectively on an average. These facts clearly indicate a better hypoglycemic activity of complexes as compared to their parent drugs which is in agreement with the earlier findings of Iqbal and co-worker 71 . This improved hypoglycemic activity may be related to smaller particle size of metal complexes than drugs as on complexation particle size is reduced which may promote the ratio of absorption of complexes in gastro-intestinal tract.
Results of the present work are also in conformity with the hypoglycemic effect of copperphenformin complex over parent drug phenformin as mentioned by Piccini et al., 70 .
These interesting observations on metalcomplexes of oral sulphonylureas used as antidiabetic agents for lowering blood sugar concentration may likely substantiate the use of these complexes after extensive clinical studies.
